Wikisage, the free encyclopedia of the second generation, is digital heritage
Rufinamide
Lennox-Gastaut is a low prevalence epileptic syndrome (1:10000), and Cochrane Epilepsy Group concluded that treatment remain unconcluside Otsuka et al (2014) state efficacious and well tolerated AED [1](cf. Alssad et Coren 2014) [2] "Rufinamide received the status of orphan drug for epilepsy in 2004 in Europe" [3]
- ↑ [http://www.epires-journal.com/article/S0920-1211(14)00228-9/pdf Rufinamide as an adjunctive therapy for Lennox-Gastaut syndrome: a randomized double-blind placebo-controlled trial in Japan]
- ↑ Exposure to rufinamide and risks of CNS adverse events in drug-resistant epilepsy: a meta-analysis of randomized, placebo-controlled trials
- ↑ [http://onlinelibrary.wiley.com/doi/10.1111/epi.12689/epdf Safety and retention rate of rufinamide in 300 patients: a single pediatric epilepsy center experience]
